Predicted mechanisms of resistance to mTOR inhibitors

The serine/threonine kinase, mTOR (mammalian Target of Rapamycin) has become a focus for cancer drug development. Rapamycins are highly specific inhibitors of mTOR and potently suppress tumour cell growth by retarding cells in G1 phase or potentially inducing apoptosis. Currently, both rapamycin and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurmasheva, R T, Huang, S, Houghton, P J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360702/
https://www.ncbi.nlm.nih.gov/pubmed/16953237
http://dx.doi.org/10.1038/sj.bjc.6603353
_version_ 1782153114439122944
author Kurmasheva, R T
Huang, S
Houghton, P J
author_facet Kurmasheva, R T
Huang, S
Houghton, P J
author_sort Kurmasheva, R T
collection PubMed
description The serine/threonine kinase, mTOR (mammalian Target of Rapamycin) has become a focus for cancer drug development. Rapamycins are highly specific inhibitors of mTOR and potently suppress tumour cell growth by retarding cells in G1 phase or potentially inducing apoptosis. Currently, both rapamycin and several analogues are being evaluated as anticancer agents in clinical trials. Results indicate that many human cancers have intrinsic resistance and tumours initially sensitive to rapamycins become refractory, demonstrating acquired resistance. Here, we consider mechanisms of resistance to inhibitors of mTOR.
format Text
id pubmed-2360702
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23607022009-09-10 Predicted mechanisms of resistance to mTOR inhibitors Kurmasheva, R T Huang, S Houghton, P J Br J Cancer Minireview The serine/threonine kinase, mTOR (mammalian Target of Rapamycin) has become a focus for cancer drug development. Rapamycins are highly specific inhibitors of mTOR and potently suppress tumour cell growth by retarding cells in G1 phase or potentially inducing apoptosis. Currently, both rapamycin and several analogues are being evaluated as anticancer agents in clinical trials. Results indicate that many human cancers have intrinsic resistance and tumours initially sensitive to rapamycins become refractory, demonstrating acquired resistance. Here, we consider mechanisms of resistance to inhibitors of mTOR. Nature Publishing Group 2006-10-23 2006-09-05 /pmc/articles/PMC2360702/ /pubmed/16953237 http://dx.doi.org/10.1038/sj.bjc.6603353 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Minireview
Kurmasheva, R T
Huang, S
Houghton, P J
Predicted mechanisms of resistance to mTOR inhibitors
title Predicted mechanisms of resistance to mTOR inhibitors
title_full Predicted mechanisms of resistance to mTOR inhibitors
title_fullStr Predicted mechanisms of resistance to mTOR inhibitors
title_full_unstemmed Predicted mechanisms of resistance to mTOR inhibitors
title_short Predicted mechanisms of resistance to mTOR inhibitors
title_sort predicted mechanisms of resistance to mtor inhibitors
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360702/
https://www.ncbi.nlm.nih.gov/pubmed/16953237
http://dx.doi.org/10.1038/sj.bjc.6603353
work_keys_str_mv AT kurmashevart predictedmechanismsofresistancetomtorinhibitors
AT huangs predictedmechanismsofresistancetomtorinhibitors
AT houghtonpj predictedmechanismsofresistancetomtorinhibitors

Ejemplares similares